ARGENX SE is 5.8x more valuable than Krystal Biotech, Inc. by market capitalization ($53.35 B vs $9.21 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KRYS | ARGX |
|---|---|---|
| Market cap | $9.21 B | $53.35 B |
| US-listed rank | #989 | #306 |
| Revenue (latest FY) | $389.13M | - |
| Net income (latest FY) | $204.83M | - |
| Net margin | 52.6% | - |
| P/E (trailing FY) | 45.0 | - |
| SEC filings | 483 | 272 |
ARGENX SE is 5.8x more valuable than Krystal Biotech, Inc. by market capitalization ($53.35 B vs $9.21 B).
Full pages: Krystal Biotech, Inc. and ARGENX SE, or browse the full rankings.